Multicentre Open Label Non-randomized Clinical Study Evaluating Pharmacokinetics, Safety, Tolerability of Multiple Intravitreal Injections of BCD-021 (CJSC BIOCAD, Russia) in Patients With Neovascular Wet Age-related Macular Degeneration

Trial Profile

Multicentre Open Label Non-randomized Clinical Study Evaluating Pharmacokinetics, Safety, Tolerability of Multiple Intravitreal Injections of BCD-021 (CJSC BIOCAD, Russia) in Patients With Neovascular Wet Age-related Macular Degeneration

Discontinued
Phase of Trial: Phase I

Latest Information Update: 04 Apr 2016

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Age-related macular degeneration
  • Focus Adverse reactions
  • Sponsors Biocad
  • Most Recent Events

    • 30 Mar 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Mar 2016 as reported by ClinicalTrials.gov
    • 30 Mar 2016 Status changed from not yet recruiting to discontinued as reported by ClinicalTrials.gov.
    • 25 May 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top